BOREAL GENOMICS INC has a total of 24 patent applications. It decreased the IP activity by 91.0%. Its first patent ever was published in 2013. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets biotechnology, organic fine chemistry and measurement are SHANGHAI SHINES PHARMACEUTICAL CO LTD, XIAMEN SPACEGEN CO LTD and VAN EIJK MICHAEL JOSEPHUS THERESIA.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 11 | |
#2 | WIPO (World Intellectual Property Organization) | 9 | |
#3 | Canada | 2 | |
#4 | EPO (European Patent Office) | 2 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Organic fine chemistry | |
#3 | Measurement | |
#4 | Chemical engineering |
# | Name | Total Patents |
---|---|---|
#1 | Marziali Andrea | 24 |
#2 | Pel Joel | 22 |
#3 | Sood Nitin | 4 |
#4 | Despotovic Milenko | 4 |
#5 | Wiggin Matthew | 3 |
#6 | Lee Mark | 2 |
Publication | Filing date | Title |
---|---|---|
WO2020251968A1 | Linked target capture | |
WO2020141464A1 | Linked target capture | |
WO2020039261A1 | Linked target capture and ligation | |
US2019264273A1 | Linked duplex target capture | |
EP3551769A2 | Linked ligation | |
WO2017168329A1 | Droplet-based linked-fragment sequencing | |
US2016122814A1 | Methods of sequencing with linked fragments | |
US2016002717A1 | Determining mutation burden in circulating cell-free nucleic acid and associated risk of disease | |
US2013344498A1 | Enrichment of nucleic acid targets |